Drug discovery of utilizing of characteristics of angiotensin II type 1 receptor blockers
| Project/Area Number |
21591065
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Kidney internal medicine
|
|---|
| Research Institution | Fukuoka University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
SAKU Keijiro 福岡大学, 医学部, 教授 (40183371)
|
|---|
| Project Period (FY) |
2009 – 2011
|
| Project Status |
Completed (Fiscal Year 2011)
|
| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2011: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2010: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2009: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Keywords | ドラックエフェクト / クラスエフェクト / イノシトールリン酸産生能 / 細胞外シグナル調節キナーゼ活性 / 洗い流し試験 / 結合能 / インバースアゴニズム / monocyte chemoattractant protein / nuclear factor kappa B / peroxisome proliferator-activated receptor |
|---|
| Research Abstract |
We analyzed the drug(molecular or differential) effects of angiotensin II type 1(AT1) receptor blockers. We found that candesartan has strong blocking effect of cell signaling after wash-out. In addition, irbesartan has a strong anti-inflammation and valsatan showed a highly selective behavior for AT1 receptor. Before designing a new ARB, we identified the olmesartan, olmesartan-related compound R239470 and R794847, which induced inverse agonism, antagonism and agonism, respectively.
|
Report
(4 results)
Research Products
(40 results)
